Elahere 100 MG/20 ML vial 20ML
Ended Awarded Last action
- Contract number
- SPE2DR26FCY9P
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $74,877
Award facts
- Contract value 100% obligated
- $74,876.96 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $74,876.96 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ELAHERE 100 mg/20 mL vials on January 12, 2026, with an ultimate completion date of February 3, 2026. This non-competitive set-aside award will be performed in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order represents a task against the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999 through December 2026 that enables the company to supply pharmaceutical products and medical supplies across multiple therapeutic domains to support military healthcare programs worldwide.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, is a subsidiary of Cencora, Inc., which also maintains a separate $999,999,999 IDC with the Defense Logistics Agency extending through December 2031. The company's federal contract portfolio demonstrates extensive capability in fulfilling specialized pharmaceutical procurement requirements for military and veteran healthcare systems, with a track record of delivering both brand-name and generic medications, vaccines, and medical supplies through competitively awarded delivery orders with firm fixed pricing. ELAHERE (mirvetuximab soravtansine), an anti-folate receptor alpha antibody-drug conjugate, represents a specialized oncology pharmaceutical used in the treatment of platinum-resistant ovarian cancer, reflecting DLA's procurement of critical therapeutic agents for Defense Health Agency beneficiaries and military treatment facilities.
Quick answers
Who was awarded contract SPE2DR26FCY9P?
SPE2DR26FCY9P was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 12, 2026.
How much is contract SPE2DR26FCY9P worth?
The government has obligated $74,877 on SPE2DR26FCY9P.
Is contract SPE2DR26FCY9P an order under another contract?
Yes. SPE2DR26FCY9P is a delivery order under SPE2DR25D1100, an indefinite delivery contract.
Was contract SPE2DR26FCY9P competed?
The extent of competition for SPE2DR26FCY9P was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award